Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Francoise Solly, MD, Catherine Koering, PhD, Aminetou mint Mohamed, PhD, Delphine Maucort-Boulch, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Pascale Flandrin-Gresta, MDPhD, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Olivier Kosmider, MD PhD, Emmanuelle Tavernier-Tardy, MDPhD, Jérôme Cornillon, MD, Denis Guyotat, MDPhD, Lydia Campos, MD PhD, Franck Mortreux, PhD, Eric Wattel, MDPhD

Blood (2015) 126 (23): 2840.

https://doi.org/10.1182/blood.V126.23.2840.2840

Published: 2015

Journal Articles

High Pro-Apoptotic Effects of 17-Allylamino-17-Demethoxy Geldanamycin (17-AAG) In Philadelphia Acute Lymphoblastic Leukemia (Ph+ ALL)

Emmanuelle Tavernier-Tardy, Pascale Flandrin, Francoise Solly, Jérôme Cornillon, Karine Augeul-Meunier, Jean-Louis Stephan, Denis Guyotat, Lydia Campos, MD, PhD

Blood (2010) 116 (21): 3226.

https://doi.org/10.1182/blood.V116.21.3226.3226

Published: 2010

Journal Articles

CD133 + Acute Myeloid Leukemia (AML) Cells Exhibit Higher Clonogenic Capacity and Higher Levels of pAKT and Bcl-2 Proteins Than Their Negative Counterpart

Francoise Solly, Lauren Rigollet, Pascale Flandrin-Gresta, Karine Augeul-Meunier, Emmanuelle Tavernier-Tardy, Nathalie Nadal, Denis Guyotat, Lydia Campos, MD, PhD

Blood (2010) 116 (21): 1721.

https://doi.org/10.1182/blood.V116.21.1721.1721

Published: 2010

Journal Articles

Activation of Multiple Signal Transduction Pathways as a Prognostic Marker in Acute Myelogenous Leukemia.

Pascale Flandrin-Gresta, MD, Lydia Campos, MD, PhD, Emmanuelle Tavernier-Tardy, MD, Amelie Duval, MD, Nathalie Nadal, MD, Denis Guyotat, MD, PhD

Blood (2007) 110 (11): 2395.

https://doi.org/10.1182/blood.V110.11.2395.2395

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

High Pro-Apoptotic Effects of 17-Allylamino-17-Demethoxy Geldanamycin (17-AAG) In Philadelphia Acute Lymphoblastic Leukemia (Ph+ ALL)

CD133 + Acute Myeloid Leukemia (AML) Cells Exhibit Higher Clonogenic Capacity and Higher Levels of pAKT and Bcl-2 Proteins Than Their Negative Counterpart

Activation of Multiple Signal Transduction Pathways as a Prognostic Marker in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

High Pro-Apoptotic Effects of 17-Allylamino-17-Demethoxy Geldanamycin (17-AAG) In Philadelphia Acute Lymphoblastic Leukemia (Ph+ ALL)

CD133 + Acute Myeloid Leukemia (AML) Cells Exhibit Higher Clonogenic Capacity and Higher Levels of pAKT and Bcl-2 Proteins Than Their Negative Counterpart

Activation of Multiple Signal Transduction Pathways as a Prognostic Marker in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only